Success Metrics

Clinical Success Rate
73.3%

Based on 11 completed trials

Completion Rate
73%(11/15)
Active Trials
0(0%)
Results Posted
36%(4 trials)
Terminated
4(25%)

Phase Distribution

Ph phase_4
8
50%
Ph phase_2
3
19%
Ph phase_1
1
6%
Ph phase_3
3
19%
Ph early_phase_1
1
6%

Phase Distribution

2

Early Stage

3

Mid Stage

11

Late Stage

Phase Distribution16 total trials
Early Phase 1First-in-human
1(6.3%)
Phase 1Safety & dosage
1(6.3%)
Phase 2Efficacy & side effects
3(18.8%)
Phase 3Large-scale testing
3(18.8%)
Phase 4Post-market surveillance
8(50.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

73.3%

11 of 15 finished

Non-Completion Rate

26.7%

4 ended early

Currently Active

0

trials recruiting

Total Trials

16

all time

Status Distribution
Completed(11)
Terminated(4)
Other(1)

Detailed Status

Completed11
Terminated4
unknown1

Development Timeline

Analytics

Development Status

Total Trials
16
Active
0
Success Rate
73.3%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (6.3%)
Phase 11 (6.3%)
Phase 23 (18.8%)
Phase 33 (18.8%)
Phase 48 (50.0%)

Trials by Status

completed1169%
terminated425%
unknown16%

Recent Activity

0 active trials
Showing 5 of 16
terminatedphase_4

Comparative Bioavailability of Myfenax® and CellCept® in Kidney Transplant Patients

NCT00991510
terminatedphase_4

Heart Spare the Nephron (STN) Study - A Study of CellCept (Mycophenolate Mofetil) and Rapamune (Sirolimus) in Heart Transplant Recipients

NCT00121784
completedphase_3

A Study to Assess Use of Zenapax (Daclizumab) and CellCept (Mycophenolate Mofetil) to Improve Kidney Function in Kidney Transplant Patients

NCT00048152
completedphase_2

Safety and Efficacy of Cellcept and Avonex as Combination Treatment in Multiple Sclerosis

NCT00324506
completedphase_2

Safety Study of Combination Therapy With Intramuscular Avonex and Oral Cellcept in Patients With Multiple Sclerosis

NCT00223301
View all 16 trials

Clinical Trials (16)

Showing 16 of 16 trials
NCT00991510Phase 4

Comparative Bioavailability of Myfenax® and CellCept® in Kidney Transplant Patients

Terminated
NCT00121784Phase 4

Heart Spare the Nephron (STN) Study - A Study of CellCept (Mycophenolate Mofetil) and Rapamune (Sirolimus) in Heart Transplant Recipients

Terminated
NCT00048152Phase 3

A Study to Assess Use of Zenapax (Daclizumab) and CellCept (Mycophenolate Mofetil) to Improve Kidney Function in Kidney Transplant Patients

Completed
NCT00324506Phase 2

Safety and Efficacy of Cellcept and Avonex as Combination Treatment in Multiple Sclerosis

Completed
NCT00223301Phase 2

Safety Study of Combination Therapy With Intramuscular Avonex and Oral Cellcept in Patients With Multiple Sclerosis

Completed
NCT00433953Phase 1

Genetic Drug Study of Mycophenolic Acid (CellCept) in Pediatric Kidney Transplant Patients

Terminated
NCT00618527Early Phase 1

Combination Therapy Using Cellcept and Rebif in RRMS

Completed
NCT00337493Phase 4

Pharmacogenetic Study of CellCept (Mycophenolate Mofetil) in Kidney Transplant Patients.

Completed
NCT00817687Phase 4

A Study of the Impact of an Early Biopsy in Patients Treated With CellCept (Mycophenolate Mofetil) After Kidney Transplantation

Completed
NCT00121810Phase 4

Kidney Spare the Nephron (STN) Study - A Study of CellCept (Mycophenolate Mofetil) and Rapamune (Sirolimus) in Kidney Transplant Recipients

Completed
NCT00118742Phase 4

Liver Spare the Nephron (STN) Study - A Study of CellCept (Mycophenolate Mofetil) and Sirolimus in Recipients of a Liver Transplant

Completed
NCT00446459Phase 2

Effects of Mycophenolate Mofetil (MMF) On Anti-HLA (Human Leukocyte Antigen)Antibody Levels In Patients Awaiting Cadaveric Renal Transplant.

Completed
NCT00737659Phase 4

CellCept® Dose Adjustment Versus Fixed Dose (Standard Care) in Renal Transplant Recipients

Unknown
NCT00683969Phase 3

A Study to Assess the Effect of CellCept (Mycophenolate Mofetil) and Reduced Corticosteroids in Controlling Symptoms of Myasthenia Gravis

Completed
NCT00408213Phase 3

A Continuation Study to Assess the Effect of CellCept in Patients With Myasthenia Gravis.

Completed
NCT00420472Phase 4

A Study of CellCept (Mycophenolate Mofetil) in Kidney Transplant Patients Switched From EC-MPS.

Terminated

All 16 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
16